GlassScriptPhysician profile
Buddy B Stokes
NPI 1003172313
$8,336.84
in general payments reported to CMS, 2019-2025
40 companies · $537 in 2025
The $537 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $1,129 · 2021: $1,738 · 2022: $1,569 · 2023: $979 · 2024: $732 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,058.95 | 2019-2024 | Xarelto |
| Abbvie INC. | $787.58 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $583.10 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $521.14 | 2019-2024 | Ozempic |
| Lilly USA, LLC | $458.91 | 2020-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $374.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $335.02 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $299.32 | 2019-2025 | Evenity, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.15 | 2020-2022 | |
| Nevro Corp. | $220.38 | 2021-2024 | Senza |
| Amarin Pharma, INC. | $210.99 | 2019-2022 | |
| Astellas Pharma US INC | $201.66 | 2019-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $181.56 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $174.81 | 2023-2025 | Rexulti, Nuedexta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buddy Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.